DK2661447T3 - Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors - Google Patents

Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors Download PDF

Info

Publication number
DK2661447T3
DK2661447T3 DK12702771.2T DK12702771T DK2661447T3 DK 2661447 T3 DK2661447 T3 DK 2661447T3 DK 12702771 T DK12702771 T DK 12702771T DK 2661447 T3 DK2661447 T3 DK 2661447T3
Authority
DK
Denmark
Prior art keywords
alphabody
ligand
cytokine
growth factor
receptor
Prior art date
Application number
DK12702771.2T
Other languages
Danish (da)
English (en)
Inventor
Ignace Lasters
Johan Desmet
Maria Henderikx
Anita Wehnert
Geert Meersseman
Original Assignee
Complix N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Complix N V filed Critical Complix N V
Application granted granted Critical
Publication of DK2661447T3 publication Critical patent/DK2661447T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK12702771.2T 2011-01-06 2012-01-06 Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors DK2661447T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011050138 2011-01-06
PCT/EP2012/050193 WO2012093172A1 (en) 2011-01-06 2012-01-06 Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors

Publications (1)

Publication Number Publication Date
DK2661447T3 true DK2661447T3 (en) 2015-11-02

Family

ID=44242740

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12702771.2T DK2661447T3 (en) 2011-01-06 2012-01-06 Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors

Country Status (9)

Country Link
US (1) US20140057830A1 (enExample)
JP (1) JP2014504869A (enExample)
CN (1) CN103339148A (enExample)
AU (1) AU2012204846B2 (enExample)
BR (1) BR112013017367A2 (enExample)
CA (1) CA2821646A1 (enExample)
DK (1) DK2661447T3 (enExample)
IN (1) IN2013MN01394A (enExample)
WO (1) WO2012093172A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
AU2013207209B2 (en) 2012-01-06 2017-02-16 Complix Nv Binding agents to intracellular target molecules
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA2888930C (en) 2012-10-22 2020-10-20 Complix Nv Polypeptides capable of cellular internalization
JP2016506361A (ja) * 2012-10-22 2016-03-03 コンプリクス エン ヴェー Ｉｌ−２３に特異的に結合するポリペプチド
WO2015179737A2 (en) 2014-05-23 2015-11-26 Kolltan Pharmaceuticals, Inc. Treatment of eosinophil or mast cell related disorders
WO2017102835A1 (en) * 2015-12-14 2017-06-22 Complix Nv Binding molecule comprising an alphabody-polypeptide and an antibody
EP4229087A1 (en) 2020-10-19 2023-08-23 Zoetis Services LLC Antibodies to canine and feline oncostatin m receptor beta and uses thereof
CN113315431B (zh) * 2021-04-22 2023-07-28 湖南工业大学 基于等价输入干扰系统的pmsm失磁故障控制方法、电机
CN114544812B (zh) * 2022-02-18 2023-06-30 复旦大学附属中山医院 一种代谢组合式标志物在诊断哮喘中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
EP2161278B1 (en) * 2008-09-08 2012-05-23 Complix N.V. Single-chain coiled coil scaffold
EP2367840B1 (en) 2008-12-08 2015-08-12 Complix N.V. Single-chain antiparallel coiled coil proteins
BR112013017363A2 (pt) * 2011-01-06 2016-08-30 Complix Sa biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira

Also Published As

Publication number Publication date
AU2012204846B2 (en) 2016-09-08
JP2014504869A (ja) 2014-02-27
CN103339148A (zh) 2013-10-02
BR112013017367A2 (pt) 2016-11-22
US20140057830A1 (en) 2014-02-27
CA2821646A1 (en) 2012-07-12
WO2012093172A1 (en) 2012-07-12
IN2013MN01394A (enExample) 2015-06-12
AU2012204846A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
DK2661447T3 (en) Alphabodies that specifically bind to cytokines or growth factors and / or cytokine or growth factor receptors
EP2661446B1 (en) Alphabody libraries and methods for producing the same
KR102320189B1 (ko) 특이적 결합 분자의 합성 라이브러리
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
US11466070B2 (en) Signalling system
JP2019501885A (ja) 多特異性抗体
WO2008124858A2 (en) Targeted receptor
US20120129715A1 (en) Gb1 peptidic libraries and methods of screening the same
EP3484927A1 (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
Finch et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics
EP2661447B1 (en) Alphabodies specifically binding to cytokines or growth factors and/or cytokine or growth factor receptors
CN102660551B (zh) 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用
KR101510831B1 (ko) 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제